COPENHAGEN, Feb 24 (Reuters) – Danish drugmaker Novo Nordisk said on Tuesday it plans to slash the U.S. list prices of its blockbuster weight-loss drug Wegovy and diabetes drug Ozempic by up to 50% and 35% respectively as of January next year. (Reporting by Louise Rasmussen, editing by Terje Solsvik)
Health
Novo Nordisk to cut US list prices of Ozempic, Wegovy as of 2027
Audio By Carbonatix
COPENHAGEN, Feb 24 (Reuters) – Danish drugmaker Novo Nordisk said on Tuesday it plans to slash the U.S. list prices of its blockbuster weight-loss drug Wegovy and diabetes drug Ozempic by up to 50% and 35% respectively as of January next year.
(Reporting by Louise Rasmussen, editing by Terje Solsvik)